The aim of our prospective study was to investigate the clinical potential of proton MR spectroscopy (1H-MRS) with an optimized TE (97 ms) in identifying IDH-mutant gliomas by detecting characteristic resonances of 2HG and its complex interplay with other clinically relevant metabolites. The gene discussed is IDH2; the disease is central nervous system cancer.